[3] In January 2019, Spectrum Pharmaceuticals sold its entire portfolio of hematology and oncology related products to Acrotech Biopharma USA, Inc., a New Jersey-based subsidiary of India's Aurobindo Pharma Ltd.

The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets.

Oct. 24, 2019 Spectrum re-submitted an updated version of its Biologics License Application (BLA)for ROLONTIS (eflapegrastim) to FDA based on 643 early-stage breast cancer patients.

Dec 27, 2018 Spectrum announced its submission of the Biologics License Application to the FDA for Rolontis (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia based on 643 early-stage breast cancer patients.

Poziotinib is a tyrosine kinase inhibitor in development for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations.

Dec 19, 2018 Spectrum announced that based on a subset of data from MD Anderson's ongoing Phase 2 study, FDA did not grant Breakthrough Therapy Designation (BTD) to Poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations.

Sep 24, 2018 Spectrum Announced the release of updated Poziotinib data From MD Anderson's Phase 2 Study in Non-Small Cell Lung Cancer Patients.